Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

BIOLOGICAL(7)
MIXED(2)
DRUG(1)
CD19 CAR-T cells
1 trial
phase_1_2
chongqing-precision-biotech-co-ltd
Anti-CD19 UCAR-NK cells
1 trial
phase_1_2
920th-hospital-of-joint-logistics-support-force-of-peoples-liberation-army-of-china
CD19 and CD22 targeted prime CAR- T cells
1 trial
phase_1_2
chongqing-precision-biotech-co-ltd
Venetoclax in combination with azacitidine and CAG
1 trial
phase_2
hematology-department-of-the-920th-hospital
BCMA targeted prime CAR-T cells
1 trial
phase_1_2
chongqing-precision-biotech-co-ltd
CD123 CAR-T cells
1 trial
phase_1_2
chongqing-precision-biotech-co-ltd
Anti-GPRC5D CAR-T cells infusion
1 trial
phase_1_2
920th-hospital-of-joint-logistics-support-force-of-peoples-liberation-army-of-china
CD19 and CD22 targeted prime CAR-T cells
1 trial
phase_1_2
chongqing-precision-biotech-co-ltd

+2 more interventions

10 unique interventions3 categories

Analytics

Trial Phases

Phase 19
Phase 210

Trial Status

Completed1
Recruiting3
Other6

Role Distribution

Principal Investigator10
PI Rate100%

Activity Timeline

Clinical Trials (10)

NCT05739188Phase 1/2Unknown
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
PrincipalinvestigatorStart date: 2023-02-07
NCT05654038Phase 1/2Unknown
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
B-Cell Lymphoblastic Leukemia/Lymphoma
PrincipalinvestigatorStart date: 2022-12-08
NCT05662956Phase 2Completed
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Acute Myeloid Leukemia
PrincipalinvestigatorStart date: 2022-12-01
NCT04782193Phase 1/2Unknown
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
B Cell Lymphoma
PrincipalinvestigatorStart date: 2021-05-23
NCT04776330Phase 1/2Recruiting
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
PrincipalinvestigatorStart date: 2021-03-07
NCT04781634Phase 1/2Recruiting
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
B-ALL
PrincipalinvestigatorStart date: 2021-03-07
NCT04265963Phase 1/2Unknown
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
PrincipalinvestigatorStart date: 2019-09-01
NCT04649983Phase 1/2Unknown
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Leukemia, B-cellLymphoma, B-Cell
PrincipalinvestigatorStart date: 2019-09-01
NCT04271410Phase 1/2Unknown
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
LeukemiaLeukemia, B-cellLeukemia, Lymphocytic, Chronic, B-Cell+2 more
PrincipalinvestigatorStart date: 2019-06-01
NCT04271644Phase 1/2Recruiting
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
PrincipalinvestigatorStart date: 2019-04-01

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Lymphoma, B-Cell3Multiple Myeloma in Relapse3Leukemia, Myeloid, Acute2Leukemia2Leukemia, B-Cell2Multiple Myeloma2Neoplasms, Plasma Cell2B-All1

Affiliations

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Cheng Qian, PhD

Chongqing University Cancer Hospital

Very Similar
11 trials

Shared therapeutic areas:

Lymphoma, B-CellLeukemiaLeukemia, B-Cell+8 more

Worked with same sponsors:

Chongqing Precision Biotech Co., Ltd
Collaborated on 7 trials
Similarity Score138%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

LeukemiaLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell+3 more
Similarity Score14%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Multiple MyelomaLeukemiaLeukemia, Myeloid, Acute+3 more
Similarity Score14%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell+1 more
Similarity Score9%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteMultiple Myeloma
Similarity Score7%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-CellLeukemia
Similarity Score7%

David Avigan, MD

Beth Israel Deaconess Medical Center

Related
17 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score7%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia
Similarity Score5%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteMultiple Myeloma
Similarity Score5%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

LeukemiaLeukemia, Myeloid, Acute
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (10)

Showing 10 of 10 trials

NCT05739188Phase 1/2PrincipalInvestigator

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Unknown
NCT05654038Phase 1/2PrincipalInvestigator

A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies

B-Cell Lymphoblastic Leukemia/Lymphoma
Unknown
NCT05662956Phase 2PrincipalInvestigator

A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

Acute Myeloid Leukemia
Completed
NCT04782193Phase 1/2PrincipalInvestigator

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma
Unknown
NCT04776330Phase 1/2PrincipalInvestigator

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Recruiting
NCT04781634Phase 1/2PrincipalInvestigator

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

B-ALL
Recruiting
NCT04265963Phase 1/2PrincipalInvestigator

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Unknown
NCT04649983Phase 1/2PrincipalInvestigator

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Leukemia, B-cellLymphoma, B-Cell
Unknown
NCT04271410Phase 1/2PrincipalInvestigator

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

LeukemiaLeukemia, B-cellLeukemia, Lymphocytic, Chronic, B-Cell+2 more
Unknown
NCT04271644Phase 1/2PrincipalInvestigator

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Recruiting

All 10 trials loaded